Cite
HARVARD Citation
Mark, M. et al. (n.d.). 798PImpact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study. Annals of oncology. p. . [Online].